Nexstim gives an update on its promising treatment results of Major Depressive Disorder

News
- 12/03/2021

Helsinki, Finland: 12 March 2021 – Nexstim Plc (NXTMH:HEX, NXTMS:STO) reports very promising clinical outcomes of the 159 patients who have completed Nexstim SmartFocus® rTMS treatment with Nexstim NBT® system for major depressive disorder (MDD).

Treatment outcomes of these 159 patients were good: 47.2% were in remission at end of treatment and 76.1% had obtained a clinical response.

These outcomes are clearly higher than what is usually reported for MDD: In a well-conducted multisite study, remission rates were 26.5-28.7 % and the patient-reported response rates were 41.5-56.4%. The patient-reported remission and response rates are also higher than those reported in a large >3800 patient series for patients completing clinical rTMS treatment (remission 29.7-36.2%, response 62.7-70.4%).

The clinical outcomes of majority of the patients treated with SmartFocus® rTMS in the United States are being collected in a registry — the information is provided by participating clinical sites using Nexstim’s SmartFocus® technology.

Further information on Nexstim’s website.